About this episode:

A new vaccine shows 70% efficacy in preventing Lyme disease, but limitations to the clinical trials put the fate of this intervention in limbo. In this episode: Anna Durbin, an expert in experimental vaccines, explains where this vaccine shows promise, where it falls short, and what could happen next for licensing and regulation.

Guest:

Dr. Anna Durbin is a professor of International Health and the director of the Johns Hopkins Center for Immunization Research.

Host:

Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs.

Show links and related content:

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial—Pfizer
Tickborne Diseases Are on the Rise—Here's What To Know—Johns Hopkins Bloomberg School of Public Health
F.D.A. Reverses Decision and Agrees to Review Moderna's Flu Vaccine—New York Times
It's Tick Season!—Public Health On Call (April 2025)

Transcript information:

Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.

Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.

Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

1045 - What's Next for a New Lyme Vaccine